Retinitis pigmentosa (RP) is a group of inherited eye diseases that gradually destroy the light-sensing cells in the retina, leading to progressive vision loss. It affects roughly 1 in 4,000 people worldwide, with an estimated 80,000 to 110,000 people living with it in the United States. Most people with RP are classified as legally blind by the age of 40.
How RP Damages Your Vision
Your retina contains two types of light-detecting cells: rods, which handle dim-light and peripheral vision, and cones, which handle color and sharp central vision. In RP, a genetic mutation first kills the rod cells. The rate of rod loss varies depending on which gene is affected, but the pattern is consistent: rods die first, then cones follow.
Cones don’t die because of the same mutation that kills the rods. Instead, once the rods are gone, oxygen that the rods would normally consume builds up in the outer retina. This excess oxygen triggers a cascade of damage. It generates highly reactive molecules that overwhelm the retina’s natural defenses, causing progressive oxidative injury to the remaining cone cells. Fluid samples from the eyes of RP patients confirm this, showing elevated markers of oxidative damage and depleted antioxidant reserves. This is why rod loss eventually leads to cone loss, even though cones themselves may carry no genetic defect.
Symptoms and How They Progress
Symptoms typically begin in late childhood or adolescence and worsen gradually over years to decades. The earliest sign is usually difficulty seeing in dim light, often called night blindness. You might notice trouble navigating a dark movie theater or adjusting when you step from a bright room into a dimly lit one.
As more rod cells are lost, blind spots develop at the edges of your vision. Over time these gaps merge, narrowing your visual field into what’s often described as tunnel vision. You can still see straight ahead, but everything to the sides fades away. This stage can last years, with the tunnel slowly closing in.
In later stages, central vision begins to decline as cone cells deteriorate. Reading, recognizing faces, and distinguishing colors all become harder. The speed of this progression depends heavily on the specific genetic type. X-linked RP (which primarily affects males) progresses fastest, while autosomal dominant forms tend to advance more slowly, with autosomal recessive forms falling in between.
Genetics and Inheritance
RP is not a single disease. It results from mutations in any of more than 80 different genes, each affecting the retina in slightly different ways. These mutations follow several inheritance patterns:
- Autosomal dominant: One copy of the mutated gene from one parent is enough to cause the disease. Each child of an affected parent has a 50% chance of inheriting it. This form tends to progress the most slowly.
- Autosomal recessive: Both parents must carry a copy of the mutation, even if neither has symptoms. Each child has a 25% chance of being affected.
- X-linked: The mutation sits on the X chromosome, so it primarily affects males. Carrier mothers typically have mild or no symptoms. This form carries the most severe prognosis, with patients about four times more likely to reach legal blindness compared to those with dominant forms, often by age 45.
- Sporadic: No family history is apparent. In large studies, sporadic cases represent the single largest group, accounting for about 42% of RP cases.
How RP Is Diagnosed
RP can be detected even before visible changes appear in the retina. The key diagnostic tool is a full-field electroretinogram (ERG), which measures the electrical response of your retina to flashes of light. In RP, these responses show characteristic delays and reduced amplitude, reflecting the loss of photoreceptor function. An ERG can establish the diagnosis early in life, when an eye exam might still look relatively normal.
Optical coherence tomography (OCT) provides a cross-sectional image of the retina’s layers. In RP, it reveals thinning of the outer retinal layers where photoreceptors live and disruption of a structure called the ellipsoid zone (EZ), which represents intact photoreceptors. The width of this intact EZ band corresponds closely to the remaining visual field. As the band narrows on successive scans, the functional field of vision shrinks along with it. Doctors often track EZ width over time because it detects small changes in progression more reliably than visual field testing alone.
Genetic testing confirms the specific mutation and inheritance pattern. This matters not only for understanding prognosis but for determining eligibility for gene-targeted treatments.
Available Treatments
There is currently no cure for RP, but several treatments can slow progression or partially restore function in specific cases.
Gene Therapy
The first FDA-approved gene therapy for an inherited retinal disease targets mutations in a gene called RPE65. Delivered as a one-time injection beneath the retina in each eye, the therapy provides a working copy of the gene to retinal cells. To be eligible, you must have confirmed mutations in both copies of the RPE65 gene (one from each parent) and enough remaining retinal cells to benefit. RPE65 mutations account for a small fraction of all RP cases, so this treatment applies to a limited group. Still, it marked a turning point as proof that gene therapy for inherited blindness is possible.
Nutritional Supplements
Research from the National Eye Institute found that a daily supplement of 15,000 IU of vitamin A palmitate can modestly slow the rate of retinal function decline in most adults with RP. This dose is not appropriate for everyone. Pregnant women should avoid it due to the risk of birth defects, and people with liver disease or already-elevated vitamin A levels need to adjust accordingly. High-dose vitamin E supplements should be avoided, as they were associated with worse outcomes in the same studies.
Optogenetic Therapy
A newer approach called optogenetics aims to make surviving retinal cells light-sensitive, essentially converting non-photoreceptor cells into substitute light detectors. Four companies have launched clinical trials for optogenetic therapies in advanced RP. At least one, Nanoscope Therapeutics, has completed a Phase 2 trial and is seeking FDA approval. These treatments are designed for people who have already lost most or all photoreceptor function, a stage where gene therapy is no longer useful.
Living With RP: Vision Aids and Adaptations
Because RP progresses over many years, most people go through a long period of adapting to changing vision. A range of tools can help maintain independence at different stages.
For tunnel vision specifically, Trifield prisms can be fitted into one lens of your glasses. These prisms redirect peripheral light into your narrowed central field, giving you some awareness of objects and movement to the sides. The other eye is left uncorrected for central tasks. This is one of the few optical devices designed specifically for the visual field pattern seen in RP.
As central vision declines, electronic magnifiers become more useful. Desktop closed-circuit television systems use a camera to display enlarged, high-contrast text on a screen, with adjustable brightness and the option to reverse black-and-white polarity. Portable versions include handheld and head-mounted units. Mouse-shaped magnifiers can be dragged across a page and connected to a computer for a larger display. Smartphone apps like Brighter and Bigger can turn a phone into a basic handheld magnifier.
Screen-reading software converts text to speech, making computers and smartphones accessible even with severe vision loss. Programs like JAWS read everything on a computer screen aloud, while built-in features like VoiceOver and ZoomText combine magnification with audio feedback.
For mobility, the traditional white cane remains essential, but electronic versions add ultrasound sensors that detect obstacles at a distance and communicate through vibration patterns. Talking GPS devices provide audio navigation for getting around independently.
For people with the most advanced RP who have only bare light perception or none at all, a retinal prosthesis (the Argus II) can provide rudimentary vision. A camera mounted on glasses sends signals to an electrode array implanted on the retina, creating patterns of light that allow some users to detect shapes, movement, and doorways.
Driving and Visual Field Requirements
One of the most practical concerns for people with RP is when they’ll need to stop driving. Because RP primarily shrinks the visual field, this is often the limiting factor rather than sharpness of central vision. Visual field requirements for a driver’s license vary significantly by state. Many states require between 110 and 140 degrees of horizontal visual field using both eyes. Some states, like California, set the bar as low as 20 degrees, while others, including Alaska, Colorado, Delaware, and Louisiana, have no formal visual field requirement at all. Michigan requires 90 degrees; Massachusetts requires 120. If you have RP, checking your state’s specific requirements is important, as the point at which driving is no longer legal may come well before you feel unable to drive.